​

Ligand Pharmaceuticals (LGND) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Ligand Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$167.13M

Latest Revenue (Q)

$115.46M

Main Segment (Y)

Royalty

Ligand Pharmaceuticals Revenue by Period

Ligand Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$167.13M27.28%
2023-12-31$131.31M-33.09%
2022-12-31$196.25M-29.19%
2021-12-31$277.13M48.66%
2020-12-31$186.42M54.98%
2019-12-31$120.28M-52.17%
2018-12-31$251.45M78.21%
2017-12-31$141.10M29.48%
2016-12-31$108.97M51.53%
2015-12-31$71.91M11.43%
2014-12-31$64.54M31.78%
2013-12-31$48.97M56.03%
2012-12-31$31.39M4.50%
2011-12-31$30.04M27.61%
2010-12-31$23.54M-39.55%
2009-12-31$38.94M42.56%
2008-12-31$27.32M111.84%
2007-12-31$12.89M-90.85%
2006-12-31$140.96M-20.18%
2005-12-31$176.61M8.01%
2004-12-31$163.51M15.85%
2003-12-31$141.14M46.05%
2002-12-31$96.64M26.59%
2001-12-31$76.34M58.68%
2000-12-31$48.11M17.63%
1999-12-31$40.90M131.07%
1998-12-31$17.70M-65.76%
1997-12-31$51.70M40.49%
1996-12-31$36.80M50.20%
1995-12-31$24.50M84.21%
1994-12-31$13.30M-

Ligand Pharmaceuticals generated $167.13M in revenue during NA 2024, up 27.28% compared to the previous quarter, and up 138.95% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$115.46M142.43%
2025-06-30$47.63M5.06%
2025-03-31$45.33M5.89%
2024-12-31$42.81M-17.37%
2024-09-30$51.81M24.76%
2024-06-30$41.53M34.07%
2024-03-31$30.98M10.24%
2023-12-31$28.10M-14.50%
2023-09-30$32.87M24.66%
2023-06-30$26.37M-40.05%
2023-03-31$43.98M62.61%
2022-12-31$27.05M-54.33%
2022-09-30$59.22M18.14%
2022-06-30$50.13M37.27%
2022-03-31$36.52M-49.61%
2021-12-31$72.47M11.78%
2021-09-30$64.83M-23.43%
2021-06-30$84.67M53.54%
2021-03-31$55.15M-21.20%
2020-12-31$69.99M67.25%
2020-09-30$41.85M1.03%
2020-06-30$41.42M24.91%
2020-03-31$33.16M22.80%
2019-12-31$27.00M8.85%
2019-09-30$24.81M-0.72%
2019-06-30$24.99M-42.54%
2019-03-31$43.48M-27.03%
2018-12-31$59.59M30.50%
2018-09-30$45.66M-49.29%
2018-06-30$90.04M60.34%
2018-03-31$56.16M11.28%
2017-12-31$50.46M51.20%
2017-09-30$33.38M19.22%
2017-06-30$28.00M-4.35%
2017-03-31$29.27M-23.35%
2016-12-31$38.19M76.63%
2016-09-30$21.62M10.75%
2016-06-30$19.52M-34.16%
2016-03-31$29.65M39.90%
2015-12-31$21.19M19.72%
2015-09-30$17.70M-3.89%
2015-06-30$18.42M26.13%
2015-03-31$14.60M-36.51%
2014-12-31$23.00M53.60%
2014-09-30$14.97M41.15%
2014-06-30$10.61M-33.53%
2014-03-31$15.96M8.29%
2013-12-31$14.74M13.32%
2013-09-30$13.01M35.75%
2013-06-30$9.58M-17.78%
2013-03-31$11.65M-14.55%
2012-12-31$13.63M113.88%
2012-09-30$6.38M11.02%
2012-06-30$5.74M1.88%
2012-03-31$5.64M-56.43%
2011-12-31$12.94M125.33%
2011-09-30$5.74M-23.07%
2011-06-30$7.46M91.56%
2011-03-31$3.90M-1.12%
2010-12-31$3.94M-49.50%
2010-09-30$7.80M33.64%
2010-06-30$5.84M-2.01%
2010-03-31$5.96M-57.37%
2009-12-31$13.98M76.90%
2009-09-30$7.90M4.04%
2009-06-30$7.59M-19.81%
2009-03-31$9.47M-23.56%
2008-12-31$12.39M136.07%
2008-09-30$5.25M9.24%
2008-06-30$4.80M-1.44%
2008-03-31$4.87M-15.53%
2007-12-31$5.77M-

Ligand Pharmaceuticals generated $115.46M in revenue during Q3 2025, up 142.43% compared to the previous quarter, and up 278.01% compared to the same period a year ago.

Ligand Pharmaceuticals Revenue Breakdown

Ligand Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 22Dec 21Dec 20Dec 19
License Fees$1.94M$2.85M$5.08M$4.38M$6.20M
Material Sales, Captisol$30.88M$104.50M$164.25M$109.96M$31.49M
Material Sales, Captisol, Core$30.88M$16.43M---
Royalty, Kyprolis$38.38M$30.12M$27.47M$25.05M-
Royalty, Other$8.95M$7.63M$11.38M$2.57M-
Service$25.53M$1.12M$23.71M$21.80M-
Royalty, Evomela$8.68M$10.20M$10.08M$5.17M-
Contract Revenue$27.48M$19.22M$63.96M$42.66M-
Royalty$108.77M$72.53M$48.93M$46.98M-
Financial Royalty Assets$13.44M----
Intangible Royalty Assets$95.33M----
Material Sales, Captisol, COVID-$88.07M---
License Fees, Milestones, and Other Product, Other-$6.11M$6.41M$4.97M$12.17M
Milestone-$9.15M$28.75M$11.52M$23.45M
Royalty, Promacta----$14.19M
License Fees, Milestones, and Product, Other----$41.82M

Ligand Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Royalty (27.87%), Intangible Royalty Assets (24.43%), Royalty, Kyprolis (9.83%), Material Sales, Captisol (7.91%), Material Sales, Captisol, Core (7.91%), Contract Revenue (7.04%), Service (6.54%), Financial Royalty Assets (3.44%), Royalty, Other (2.29%), Royalty, Evomela (2.22%), and License Fees (0.50%).

Quarterly Revenue by Product

Product/ServiceSep 25Jun 25Mar 25Dec 24Sep 24Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Sep 20Jun 20Mar 20Sep 19Jun 19Mar 19
Rylaze$3.56M$2.86M$3.12M$3.89M$3.03M$2.61M$2.10M$2.32M$1.65M-----------
Teriparatide Injection$2.63M$2.30M$1.19M$2.38M$3.61M$3.50M$4.07M$5.50M$2.91M-----------
Royalty$46.59M$36.40M$27.49M$77.06M$31.71M$20.43M$17.15M$21.04M$19.84M$17.96M$13.70M$15.65M$8.62M$7.11M$9.01M$7.18M$6.57M---
Material Sales, Captisol$10.67M$8.29M$13.46M$24.63M$6.25M$5.22M$10.62M$26.88M$35.95M$29.55M$12.12M$35.09M$62.51M$31.27M$23.39M-----
Kyprolis$11.62M$8.80M$4.72M$11.60M$8.10M$6.23M$9.12M$7.13M$4.62M$8.82M$5.44M$4.29M$6.92M$5.48M$4.41M-----
Intangible Royalty Assets$40.16M$30.08M$21.59M$68.78M$26.55M---------------
Financial Royalty Assets$6.42M$6.31M$5.90M$8.29M$5.16M---------------
Evomela$1.89M$1.47M$1.98M$1.75M$2.36M$2.55M$3.12M$2.39M$2.70M$2.67M$2.19M$2.33M$1.80M$1.20M$1.58M-----
Contract Revenue$131.00K$716.00K$16.20M$-20.87M$10.30M$9.91M$19.88M$14.09M$13.55M$16.77M$9.45M$5.19M$2.13M-------
Royalty, Other---$6.67M$2.27M$3.33M$2.27M$3.78M$1.42M$619.00K$1.81M$4.16M$983.00K$492.00K$280.00K$501.00K$584.00K---
License Fees-----$508.00K$114.00K$-2.31M$460.00K$1.61M$3.09M$200.00K$1.05M$1.04M$158.00K-----
License Fees, Milestones, and Product, Other, Product, Other-----$208.00K$789.00K$1.21M$1.58M$2.56M$1.65M$1.54M$1.84M$995.00K------
Material Sales, Captisol, COVID-------$23.58M$32.37M$26.22M$5.90M---------
Material Sales, Captisol, Core-----$5.22M$10.62M$3.30M$3.58M$3.33M$6.23M---------
Milestone------$15.30M$-4.87M$3.66M$1.27M$9.09M$7.42M$3.60M$8.42M$960.00K-----
Contract Revenue, Service--------$4.97M$5.45M$5.15M$4.83M$7.36M$5.46M$7.34M-----
Promacta-------------------$14.19M
LicenseFeesMember---------------$660.00K$975.00K---
LicenseFeesMilestonesandProductOtherProductOtherMember---------------$1.06M$821.00K---
MaterialSalesCaptisolMember---------------$24.47M$21.11M---
MilestoneMember---------------$3.47M$334.00K---
Service---------------$4.58M$3.36M---

Ligand Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Royalty (37.67%), Intangible Royalty Assets (32.47%), Kyprolis (9.39%), Material Sales, Captisol (8.63%), Financial Royalty Assets (5.20%), Rylaze (2.88%), Teriparatide Injection (2.13%), Evomela (1.53%), and Contract Revenue (0.11%).

Ligand Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ACADACADIA Pharmaceuticals$957.80M$278.63M
ADMAADMA Biologics$426.45M$134.22M
MIRMMirum Pharmaceuticals$336.89M$133.01M
LGNDLigand Pharmaceuticals$167.13M$115.46M
NAMSNewAmsterdam Pharma$45.56M$19.14M
PRAXPraxis Precision Medicines$8.55M-
CRNXCrinetics Pharmaceuticals$1.04M$143.00K
SLNOSoleno Therapeutics-$66.02M
VKTXViking Therapeutics--
DYNDyne Therapeutics--
BLTEBelite Bio--

LGND Revenue FAQ

What is Ligand Pharmaceuticals’s yearly revenue?

Ligand Pharmaceuticals's yearly revenue for 2024 was $167.13M, representing an increase of 27.28% compared to 2023. The company's yearly revenue for 2023 was $131.31M, representing a decrease of -33.09% compared to 2022. LGND's yearly revenue for 2022 was $196.24M, representing a decrease of -29.19% compared to 2021.

What is Ligand Pharmaceuticals’s quarterly revenue?

Ligand Pharmaceuticals's quarterly revenue for Q3 2025 was $115.46M, a 142.43% increase from the previous quarter (Q2 2025), and a 122.85% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $47.63M, a 5.06% increase from the previous quarter (Q1 2025), and a 14.68% increase year-over-year (Q2 2024). LGND's quarterly revenue for Q1 2025 was $45.33M, a 5.89% increase from the previous quarter (Q4 2024), and a 46.34% increase year-over-year (Q1 2024).

What is Ligand Pharmaceuticals’s revenue growth rate?

Ligand Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was -14.83%, and for the last 5 years (2020-2024) was -10.35%.

What are Ligand Pharmaceuticals’s revenue streams?

Ligand Pharmaceuticals's revenue streams in c 24 are License Fees, Material Sales, Captisol, Material Sales, Captisol, Core, Royalty, Kyprolis, Royalty, Other, Service, Royalty, Evomela, Contract Revenue, Royalty, Financial Royalty Assets, and Intangible Royalty Assets. License Fees generated $1.94M in revenue, accounting 0.50% of the company's total revenue, down -31.77% year-over-year. Material Sales, Captisol generated $30.88M in revenue, accounting 7.91% of the company's total revenue, down -70.45% year-over-year. Material Sales, Captisol, Core generated $30.88M in revenue, accounting 7.91% of the company's total revenue, up 87.98% year-over-year. Royalty, Kyprolis generated $38.38M in revenue, accounting 9.83% of the company's total revenue, up 27.43% year-over-year. Royalty, Other generated $8.94M in revenue, accounting 2.29% of the company's total revenue, up 17.19% year-over-year. Service generated $25.53M in revenue, accounting 6.54% of the company's total revenue, up 2185.85% year-over-year. Royalty, Evomela generated $8.68M in revenue, accounting 2.22% of the company's total revenue, down -14.88% year-over-year. Contract Revenue generated $27.48M in revenue, accounting 7.04% of the company's total revenue, up 42.94% year-over-year. Royalty generated $108.77M in revenue, accounting 27.87% of the company's total revenue, up 49.98% year-over-year. Financial Royalty Assets generated $13.44M in revenue, accounting 3.44% of the company's total revenue Intangible Royalty Assets generated $95.33M in revenue, accounting 24.43% of the company's total revenue

What is Ligand Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Ligand Pharmaceuticals was Royalty. This segment made a revenue of $108.77M, representing 27.87% of the company's total revenue.